Background {#Sec1}
==========

Subcutaneous insertable cardiac monitors (ICMs) continuously record ECG for up to 3 years and are used clinically for the detection of infrequent arrhythmias and atrial fibrillation management. The traditional settings for ICM insertion procedures have been the cardiac catheterization (cath) lab, the electrophysiology (EP) lab and the operating room (OR) - the same facilities used for more complex cardiac device implants, such as pacemakers, cardiac resynchronization therapy devices, and implantable cardioverter defibrillators. This practice became widespread due to the larger size of early ICM models. However, miniaturization of ICM devices has resulted in a less invasive insertion procedure, enabling relocation of device insertion within the hospital to clean rooms, procedure rooms and holding areas, and to practice offices outside the hospital walls \[[@CR1]\]. This approach is appealing because it could reduce costs related to the procedure and increase physician and patient convenience and satisfaction \[[@CR2], [@CR3]\].

To further evaluate the safety of Reveal LINQ ICM insertion within the hospital, but outside the traditional settings, we built upon previous literature to conduct the first prospective, international multi-site trial to assess the rate of adverse events through 3 months post device insertion. The study was mainly conducted in Europe and collected patient, physician, and detailed staff procedure time interval data to document the resources necessary for the procedure.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The Reveal LINQ™ In-Office 2 (RIO 2) International study (NCT02412488) was a single arm, multicenter, interventional post-market study. Patients at least 18 years of age who were indicated for continuous arrhythmia monitoring with an ICM, and who were willing to undergo ICM insertion in the hospital, but outside the cath/EP lab or OR were enrolled between September 2015 and May 2016.

Patients were followed for 90 days after ICM insertion with scheduled in-person visits at days 30 and 90, and unscheduled visits as needed. At each follow-up, the patient and insertion site were evaluated, and device and/or procedure related adverse events were documented.

The primary endpoint was the occurrence of untoward events, defined as a composite of unsuccessful ICM insertion and complications related to the Reveal LINQ ICM and/or insertion procedure. Complication was defined as an adverse event (AE) resulting in death, involving termination of significant device function, or requiring invasive intervention. Infection was categorized as deep incision site or superficial. Deep incision site infections were defined as pain, redness or drainage at the incision site that required the device to be removed or IV antibiotics to be administered. Superficial infections were characterized by redness beyond procedure expectation and administration of oral antibiotics. An independent Clinical Events Committee comprised of electrophysiologists and infection specialists who were not study investigators determined whether each event met the primary endpoint.

Ancillary objectives included summarizing resource utilization, procedure duration, physician experience, and all device and procedure related adverse events, regardless of severity.

Ethics and consent to participate {#Sec4}
---------------------------------

All patients provided written informed consent to the study protocol that was approved by the Human Research Ethics Committee of each participating institution.

Insertion procedure {#Sec5}
-------------------

ICM insertion (Reveal LINQ™, model LINQ11, Medtronic, Inc.) was performed in accordance with the manufacturer's instructions. Device insertion took place in a hospital location that was outside the cath/EP lab or OR such as a procedure room, holding area or office. Throughout the manuscript, these locations are referred to as "out-of-lab". Physicians were required to use the incision and insertion tools, and to insert the device at one of the anatomical locations listed in the Instructions for Use. The protocol also mandated that physicians wear sterile gloves, gown and mask during device insertion, and use hand antiseptic prior to the procedure. Patients were required to be draped or wear a mask during the procedure. Sedation was not allowed, but local anesthesia and anxiolytic medications were permitted and used in accordance with physician and patient preference. Use of prophylactic antibiotics was left to physician discretion and institution specific infection control protocols. The incision was closed using adhesive strips, surgical glue, sutures or staples.

Procedure duration and resource utilization {#Sec66}
-------------------------------------------

Procedure time intervals, procedural details, supply use, and staffing resources were recorded during pre-insertion preparation, and post-insertion activities. The time intervals characterized were: (1) Visit duration: time from patient check-in to patient discharge; (2) Process time: time from start of patient preparation to skin closure; (3) Procedure room time: time from when the patient enters the procedure room to when the patient leaves the procedure room; (4) Patient preparation: time from the start of the patient preparation to the completion of patient preparation (including the time required for clinical assessment, changing clothes and surgical site preparation); (5) Education time: time required to educate the patient with respect to their LINQ system and their incision site.

Physician questionnaire {#Sec7}
-----------------------

Physicians were required to complete a questionnaire following each ICM insertion procedure that assessed subject response, procedure delays, and physician satisfaction. See Additional file [1](#MOESM1){ref-type="media"} for a listing of specific questions asked.

Sample size and statistical analysis {#Sec8}
------------------------------------

Based on previous studies, it was anticipated that: 1) there would be no failed device insertion attempts, 2) the rate of untoward events would be similar (roughly 2%) when device insertion occurred inside or outside the cath/EP lab or OR setting, and 3) the attrition rate would be 10%. A sample size of 204 patients was computed based on the exact method to provide a target one-sided upper 95% confidence boundary within 3% of a point estimate based on the above assumptions. Additionally, a sample size of 204 patients provided an 87% chance to detect a rare LINQ™ insertion related complication occurring at a true underlying rate of 1%, and a 64% chance to detect a rare complication occurring at a true underlying rate of 0.5%.

The exact binomial method was used to construct a 95% two-sided confidence interval for the untoward event rate. Patients were considered evaluable for the primary endpoint if they had an event meeting the primary endpoint, completed the 90-day in-person visit, or had their ICM explanted during the follow-up period.

Results {#Sec9}
=======

Study population {#Sec10}
----------------

The study enrolled 192 patients at 12 centers in Europe \[Germany (3), Italy (3), the Netherlands (2), Spain (1), Sweden (1), and the United Kingdom (2)\], 3 centers in Canada, and 2 centers in Australia between September 2015 and May 2016. Enrollment was ended early (prior to reaching the target sample size of 204) due to a lower than expected attrition rate between the time of enrollment and device insertion. Of the 192 patients enrolled, 191 underwent an ICM insertion attempt out-of-lab. All 191 insertion attempts were successful. Enrollment and follow-up of study participants is summarized in Fig. [1](#Fig1){ref-type="fig"}. Mean follow up was 3.3 ± 0.7 months, with 98% compliance to study visits.Fig. 1Enrollment and follow-up of study participants

Patient characteristics and the primary indication for an ICM device are displayed in Table [1](#Tab1){ref-type="table"}. Of the 191 patients with an ICM insertion, 45.5% were female. The most common indication was syncope (53.9%), followed by cryptogenic stroke or TIA (17.3%).Table 1Baseline patient characteristics and ICM indicationCharacteristicTotal (*N* = 191)Sex n (%) Male104 (54.5%) Female87 (45.5%)Physical Exam Findings Mean ± Standard Deviation Age (years)63.8 ± 26.9 Body mass index (kg/m^2^)27.9 ± 4.8 Systolic blood pressure (mm Hg)138.2 ± 21.6 Diastolic blood pressure (mm Hg)78.6 ± 10.6Primary Indication n (%) Atrial fibrillation ablation monitoring3 (1.6%) Atrial fibrillation management18 (9.4%) Cryptogenic stroke or TIA33 (17.3%) Palpitations7 (3.7%) Suspected atrial fibrillation15 (7.9%) Syncope103 (53.9%) Ventricular tachycardia2 (1.0%) Other indication10 (5.2%)

Procedural details {#Sec11}
------------------

Most device insertions took place in a procedure room (78%) followed by a holding area (12%, Fig. [1](#Fig1){ref-type="fig"}). Antibiotics were administered in 44.0% of patients prior to ICM insertion. In all cases, antibiotics were administered intravenously. Local anesthesia was used in 100% of insertion procedures, whereas anxiolytic use only occurred in one patient (0.5%). Most patients were draped during device insertion (80.6%), and almost all physicians wore a mask (99.5%), gown (89.5%), and surgical head covering (90.6%). Despite some deviations from the established protocol during patient preparation, no apparent increase in the risk of adverse events was established. For 88.5% of procedures, no device repositioning was required. When repositioning was necessary (11.5% of procedures), one attempt was sufficient to achieve adequate sensing. The device was inserted 45 degrees relative to the sternum over the 4th intercostal space in 93.7% of patients. Adhesive strips were the most common closure method used (64.9% of patients) followed by sutures (28.3%, Table [2](#Tab2){ref-type="table"}). Post-procedure antibiotic use was uncommon (1.6%); when used, it was administrated intravenously.Table 2ICM insertion procedure detailsProcedure ElementPatients (*N* = 191)Surgical site preparation^a^ None13 (6.8%) Shaved with razor50 (26.2%) Clipped16 (8.4%) ChloraPrep (chlorohexidine gluconate solution)85 (44.5%) Providone-iodine107 (56.0%) Other11 (5.8%)Patient preparation^a^ None0 (0.0%) Mask89 (46.6%) Gown78 (40.8%) Drape154 (80.6%) Surgical head covering59 (30.9%)Insertion physician preparation^a^ None0 (0.0%) Surgical hand antiseptic in the room69 (36.1%) Surgical hand antiseptic outside the room34 (17.8%) Traditional surgical scrub in the room48 (25.1%) Traditional surgical scrub outside the room72 (37.7%)Insertion physician preparation materials^a^ None0 (0.0%) Mask190 (99.5%) Gown171 (89.5%) Surgical head covering173 (90.6%) Single layer of gloves134 (70.2%) Double layer of gloves57 (29.8%) Other7 (3.7%)Did patient preparation take place in the procedure room? No18 (9.4%) Yes173 (90.6%)Location of inserted device 45-degree relative to sternum over 4th intercostal space179 (93.7%) Parallel to sternum over 4th intercostal space11 (5.8%) Inframammary fold0 (0.0%) V1 ECG location0 (0.0%) V2 ECG location0 (0.0%) Other location1 (0.5%)Number of repositioning/modifications during procedure 0169 (88.5%) 122 (11.5%) 20 (0.0%)Closure Method^a^ No closure method used0 (0.0%) Sutures54 (28.3%) Adhesive strips124 (64.9%) Surgical glue18 (9.4%) Staple(s)0 (0.0%)Location of post-procedure education Same room as procedure115 (60.2%) Dedicated recovery room59 (30.9%) Exam room1 (0.5%) Waiting area3 (1.6%) Other location13 (6.8%)^a^Categories are not mutually exclusive and may sum to more than 100%

Procedure time intervals {#Sec12}
------------------------

The total visit duration (time from check-in to discharge) was 115.4 ± 73.6 min \[median: 106.0, IQR: 55--161 min\]. Patient preparation accounted for 19.6 ± 25.6 min \[median: 10.0 IQR: 5--20 min\] and patient education accounted for 13.1 ± 7.9 min \[median: 10.0, IQR: 8--15 min\] of the overall visit duration on average. The distribution of procedure time intervals is displayed in Fig. [2](#Fig2){ref-type="fig"}. Patient preparation and patient education took place in the procedure room for 90.6 and 60.2% of patients, respectively. Procedure room time was 54.1 ± 43.1 min \[median: 35.5, IQR: 24--66 min\].Fig. 2Distribution of procedure time intervals. Visit duration is the time from patient check-in to discharge. Process duration is the time from the start of patient preparation to completion of the insertion procedure (skin closure). Procedure room occupancy is the time from when the patient enters the procedure room to the time the patient leaves the procedure room. Patient preparation time is the time from the start of patient preparation to the time patient preparation is completed. Education duration is the total time required to educate the patient on the use of their ICM device and care of their insertion wound. The left and right box dimensions are the interquartile (IQR) range. Open circles represent individual patients

Staffing resources {#Sec13}
------------------

Staffing resources during pre-insertion, device insertion, and post-insertion activities are displayed in Table [3](#Tab3){ref-type="table"}. The predominant staffing resources for pre-insertion activities included registered nurses (68.1% of procedures) and physicians (58.6% of procedures). Physicians also participated in the majority (82.2%) of device insertions. Cardiovascular/surgical technologists and physicians most commonly completed post-insertion activities (52.9 and 36.1% of procedures, respectively). The mean physician time was 10.4 ± 9.6 \[median: 9.0, IQR: 5--13\] minutes for pre-insertion activities, and 12.6 ± 4.8 \[median: 14.0, IQR: 10--15\] minutes for post-insertion activities when physicians were involved in these aspects of the procedure.Table 3Staffing resources for ICM insertionStaffing ResourcePre-Insertion\
n (%)Device Insertion\
n (%)Post-Insertion\
n (%)Physician112 (58.6%)157 (82.2%)69 (36.1%)Physician assistant48 (25.1%)46 (24.1%)46 (24.1%)Nurse practitioner22 (11.5%)18 (9.4%)28 (14.7%)Registered nurse130 (68.1%)107 (56.0%)43 (22.5%)CV/OR technologist^a^52 (27.2%)54 (28.3%)101 (52.9%)Medical assistant11 (5.8%)5 (2.6%)4 (2.1%)Other0 (0.0%)0 (0.0%)1 (0.5%)^a^ Cardiovascular/surgical technologist

Primary objective {#Sec14}
-----------------

Of the 191 patients who received an ICM, 15 were excluded from the primary analysis due to premature exit (10 lost to-follow-up, 5 requested withdrawal from the study) without experiencing an untoward event. Among the 176 patients evaluable for the primary objective there were no untoward events. Thus, the rate of untoward events was 0% with a 95% confidence interval ranging from 0 to 2.1%. A missing data sensitivity analysis indicated that patients excluded from the analysis cohort were extremely unlikely to have had an untoward event.

ICM related adverse events {#Sec15}
--------------------------

Of the 191 patients with an ICM insertion, there were four device and/or procedure related adverse events in four patients (Table [4](#Tab4){ref-type="table"}); none met the primary endpoint definition. One of the incision site hemorrhage events was resolved when the dressing was changed; the patient was given oral acetaminophen. At the time of the procedure, the patient was taking on antiplatelet therapy. The other incision site hemorrhage event was resolved by applying pressure; the patient was on oral anticoagulation therapy at the time of the procedure. One patient experienced presyncope following incision closure due to pain during the procedure, despite administration of an extra dose of lidocaine. The patient's blood pressure was normalized within minutes by tilt/raising the procedure bed and by giving the patient several glasses of water. Finally, no further actions were taken for the implant site pain event. There were no migrations, infections or complications related to the LINQ system or LINQ insertion procedure observed during the study.Table 4Device and/or procedure related adverse eventsDevice/procedure related eventsAdverse EventsComplicationsImplant site pain1 (1, 0.52%)0 (0, 0%)Incision site hemorrhage2 (2, 1.05%)0 (0, 0%)Presyncope1 (1, 0.52%)0 (0, 0%)TOTAL4 (4, 2.09%)0 (0, 0%)

Physician questionnaire {#Sec16}
-----------------------

Responses to the physician questionnaire are displayed in Table [5](#Tab5){ref-type="table"}. Physicians reported that 85.9% of procedures were not delayed over 15 min. Most physicians (90.6%) found the procedure room facility to be convenient or very convenient, and all physicians were satisfied or very satisfied with the insertion environment. Physicians perceived patients to respond well to device insertion, with 71.2% reporting patients having a very positive response, and 28.8% reporting patients having a positive response.Table 5Physician questionnaire responsesQuestionnaire ItemSurveys\
(*N* = 191)How well did subject respond to LINQ insertion n (%) Very positive136 (71.2%) Positive55 (28.8%) Neutral0 (0.0%) Negative0 (0.0%) Very negative0 (0.0%) No response0 (0.0%)Procedure delay \> 15 min n (%) Yes27 (14.1%) No164 (85.9%) No Response0 (0.0%)Estimated physician work time during "pre-service period" (minutes) Mean ± Standard Deviation14.9 ± 14.3 Median \[Interquartile Range\]10.0 \[5.0--15.0\]Estimated physician work time during "post-service period" (minutes) Mean ± Standard Deviation14.1 ± 10.9 Median \[Interquartile Range\]15.0 \[5.0--15.0\]Convenience of facility n (%) Very convenient136 (71.2%) Convenient37 (19.4%) About the same18 (9.4%) Inconvenient0 (0.0%) Very inconvenient0 (0.0%) No response0 (0.0%)Environment satisfaction n (%) Very satisfied163 (85.3%) Satisfied28 (14.7%) Neutral0 (0.0%) Dissatisfied0 (0.0%) Very dissatisfied0 (0.0%) No response0 (0.0%)

Discussion {#Sec17}
==========

The RIO2 International study evaluated the safety of performing Reveal LINQ ICM insertions in-hospital, but outside the traditional procedure settings. It is the first study to characterize resource utilization, procedure time intervals, and physician satisfaction from multiple centers across different geographies, including Europe, Canada and Australia. All 191 insertion attempts were successful, and no untoward events were observed among the 176 patients evaluable for the primary endpoint during a follow-up period of 3 months. Additionally, there was high compliance with the protocol specified insertion procedure. Importantly, even under circumstances with deviations from protocol, there was no increase in the risk of adverse events, punctuating the benign nature of the insertion procedure. As such, these results provide strong evidence that the Reveal LINQ ICM insertion can be safely performed out-of-lab within the hospital by following good sterile technique and the manufacturer's instructions. Other studies have assessed procedure safety outside the traditional hospital settings. In the randomized Reveal LINQ In-Office 2 (RIO 2) study performed in the United States, low rates of untoward events were observed when device insertion occurred in an office outside the hospital (*n* = 251; 0.8%) or in the traditional hospital setting (*n* = 231; 0.9%), with no difference between groups \[[@CR3]\]. Two observational studies (performed in Denmark and Australia) compared the safety of ICM insertions performed in a hospital procedure room vs. EP lab and also reported low rates of across insertion environments (0.6--1.7%), with no significant differences between settings \[[@CR4], [@CR5]\]. Absent or low complication rates have been observed in three single arm studies in which all device insertions occurred in either a hospital holding area or procedure room (0.0--0.8%) \[[@CR6]--[@CR8]\]. Importantly, the above findings demonstrate similar or lower complication rates than were observed in a combined analysis of the Reveal LINQ Usability and Reveal LINQ Registry studies (0.7 and 1.6%, respectively), where most device insertions occurred in a cath/EP lab \[[@CR9]\]. Finally, a recent analysis of the multi-center Reveal LINQ Registry in a larger population (*N* = 1222) confirmed these observations, with 0.5% vs 1.0% of complications occurring in patients with procedures performed outside of the EP/cath lab vs in the EP/cath lab, respectively \[[@CR10]\]. Together, these findings suggest that insertion of miniaturized ICMs can be moved outside the traditional hospital settings without compromising patient safety.

It is notable that no infections were observed in the present investigation, even under circumstances requiring device repositioning and despite pre-procedure antibiotics only being administered in 44% of patients. This corresponds with previous studies reporting low infection rates across insertion environments regardless of antibiotic use. Specifically, no infections were observed when an ICM was inserted in either the office (*n* = 251) or traditional hospital setting (*n* = 231) in the randomized RIO 2 US study. In that investigation, prophylactic antibiotics were administered to approximately 45% of patients, and the rate did not differ between groups \[[@CR3]\]. In addition, the Reveal LINQ Registry showed an infection rate of 0.7% among patients who had the procedure performed out-of-lab, and 0.5% for those located in-lab, with similar infection rates observed in patients irrespective of prophylactic antibiotic administration \[[@CR10]\]. An interim analysis of the randomized LOOP trial did demonstrate a higher rate of infections following device insertion in a procedure room vs. EP lab (1.6% vs. 0.1%, *p* = 0.004) despite administration of pre-procedural antibiotics in over 95% of patients \[[@CR4]\]. However, the infection rate in the procedure room remained low and comparable to rates observed in-lab in other studies \[[@CR9], [@CR10]\]. LOOP also showed a trend for fewer adverse events, including infections, with an increase in physician experience. Lastly, two single arm studies where device insertion occurred in a hospital holding area or procedure room observed infection rates of 0.0 and 0.8% when prophylactic antibiotics were used in none and all insertion procedures, respectively \[[@CR6], [@CR7]\]. Together, these data suggest that infection rates with miniaturized ICM insertion are low (≤1.6%) across insertion environments irrespective of antibiotic prophylaxis.

One of the novelties in the present investigation was the characterization of time intervals during the different steps of the patient care pathway across multiple centers and geographies (patient preparation, procedure room occupancy, process time, education, and total visit duration). We observed that device insertion could be completed efficiently out-of-lab with an average visit duration of 115 min, procedure room occupancy time of 54 min, and process duration of 29 min (from patient preparation to skin closure). Others have reported on room occupancy times and have found similar results (55--58 min) \[[@CR2], [@CR11]\]. Moreover, in the present study physicians reported few delays over 15 min. This corresponds with findings from the RIO 2 US study, where physicians reported fewer delays when a miniaturized ICM was inserted in an office vs. in-lab \[[@CR3]\]. Together, these observations suggest that moving device insertion outside the traditional hospital settings can result in time savings.

Another interesting finding was the involvement of non-physician personnel throughout the care pathway. Although physicians participated in most device insertions, registered nurses and cardiovascular/surgical technologists were predominant in performing pre- and post-insertion activities, respectively. Other single-center studies have also described successful experiences with non-physician providers inserting miniaturized ICMs in ambulatory settings in terms of safety, improved patient flow, reduced costs, and better allocation of resources \[[@CR6], [@CR11], [@CR12]\].

Finally, physician perception of performing the procedure outside the traditional settings was very positive in terms of satisfaction with the environment, convenience, and positive feedback from patients. Results from the RIO 2 randomized study, comparing Reveal LINQ insertions performed in-office vs in the traditional hospital settings, also showed improved patient and physician experience with in-office insertions \[[@CR3]\].

Limitations {#Sec18}
-----------

The main limitation of the study is its nonrandomized and single arm nature. However, safety of in-lab device insertion has been well established in previous investigations. Another limitation is the fact that the sample size was lower than estimated (191 vs. 204). In addition, the primary endpoint could not be ascertained in 15 patients due to early study withdrawal. However, patients were free from adverse events at the time of study withdrawal and the low untoward rate observed in those who were assessable would indicate that these patients were highly unlikely to have experienced an untoward event. Lastly, the study did not include a standardized approach to collect costs, so the hospital cost burden could not be estimated.

Conclusions {#Sec19}
===========

Findings from the RIO 2 International study, the first prospective, international, multicenter trial of its kind, add to a growing body of evidence that the Reveal LINQ ICM can be safely and efficiently inserted outside the traditional hospital settings.
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===============
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AE

:   Adverse event

Cath lab

:   Cardiac catheterization laboratory

CV/OR technologist

:   Cardiovascular/surgical technologist

EP lab

:   Electrophysiology laboratory

ICM

:   Insertable cardiac monitor

In-lab

:   Inside a cardiac catheterization laboratory, electrophysiology laboratory or operating room

IQR

:   Interquartile range

OR

:   Operating room

Out-of-lab

:   Outside a cardiac catheterization laboratory, electrophysiology laboratory or operating room

RIO 2

:   Reveal LINQ™ in-office 2
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